Bone marrow transplantation for acute lymphoblastic leukaemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Acute lymphoblastic leukaemia (ALL) is a significant hematologic malignancy.
• Bone marrow transplantation (BMT) is a potential curative therapy for ALL.
• Graft-versus-host disease and disease relapse are major complications of BMT.

Purpose of the Study:

• To evaluate the efficacy and safety of BMT in patients with ALL.
• To assess the long-term outcomes of BMT for ALL.
• To identify the primary obstacles to successful BMT in ALL.

Main Methods:

• Twenty patients with ALL underwent BMT.
• Donors included HLA/MLC compatible siblings, an identical twin, and a parent.
• Patient outcomes were monitored for complications and disease status.

Main Results:

• Thirteen of twenty patients remain in remission post-transplantation.
• Mortality was low, with deaths due to graft-versus-host disease and pneumonitis.
• Disease relapse occurred in four patients, with a 35% actuarial disease-free survival at 1126 days.

Conclusions:

• BMT is associated with low procedural morbidity and mortality in ALL patients.
• Disease recurrence is the primary limitation to achieving permanent remission after BMT for ALL.
• Further strategies are needed to overcome ALL relapse post-transplantation.